X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4277) 4277
Book Review (741) 741
Newsletter (339) 339
Publication (228) 228
Newspaper Article (33) 33
Book Chapter (9) 9
Conference Proceeding (9) 9
Dissertation (4) 4
Magazine Article (4) 4
Trade Publication Article (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olanzapine (4240) 4240
index medicus (3296) 3296
humans (2733) 2733
schizophrenia (2258) 2258
psychiatry (2231) 2231
male (2073) 2073
female (1763) 1763
antipsychotic agents - therapeutic use (1514) 1514
pharmacology & pharmacy (1489) 1489
adult (1462) 1462
risperidone (1346) 1346
antipsychotic agents - adverse effects (1257) 1257
schizophrenia - drug therapy (1196) 1196
neurosciences (1029) 1029
middle aged (1008) 1008
haloperidol (1003) 1003
antipsychotic agents - administration & dosage (978) 978
clozapine (964) 964
double-blind (948) 948
drug therapy (860) 860
treatment outcome (814) 814
clinical neurology (769) 769
atypical antipsychotics (700) 700
dosage and administration (693) 693
animals (688) 688
antipsychotic drugs (658) 658
benzodiazepines - therapeutic use (633) 633
antipsychotics (615) 615
psychotropic drugs (586) 586
adolescent (554) 554
quetiapine (553) 553
drugs (552) 552
research (549) 549
antipsychotic agents - pharmacology (526) 526
aged (516) 516
benzodiazepines - adverse effects (503) 503
rats (496) 496
bipolar disorder (483) 483
benzodiazepines - administration & dosage (476) 476
dose-response relationship, drug (476) 476
efficacy (441) 441
care and treatment (438) 438
double-blind method (415) 415
neuroleptics (410) 410
analysis (406) 406
risk factors (403) 403
psychiatric status rating scales (393) 393
aripiprazole (383) 383
complications and side effects (382) 382
risperidone - therapeutic use (377) 377
benzodiazepines (366) 366
psychotic disorders - drug therapy (355) 355
drug therapy, combination (348) 348
bipolar disorder - drug therapy (345) 345
young adult (342) 342
drug administration schedule (339) 339
mental disorders (338) 338
time factors (325) 325
clinical trials (324) 324
medicine & public health (316) 316
pirenzepine - analogs & derivatives (308) 308
benzodiazepines - pharmacology (306) 306
placebo (306) 306
schizophrenic psychology (300) 300
weight gain - drug effects (299) 299
quetiapine fumarate (292) 292
rats, sprague-dawley (272) 272
antipsychotic (260) 260
health aspects (257) 257
psychosis (257) 257
risperidone - adverse effects (257) 257
psychopharmacology (255) 255
ziprasidone (253) 253
weight gain (251) 251
antipsychotic-drugs (235) 235
trial (232) 232
schizoaffective disorder (230) 230
medical research (218) 218
risperidone - administration & dosage (214) 214
placebo-controlled trial (213) 213
pharmacology (212) 212
dibenzothiazepines - therapeutic use (210) 210
dopamine (209) 209
pharmacology/toxicology (205) 205
safety (205) 205
patients (201) 201
retrospective studies (201) 201
side effects (199) 199
patient outcomes (198) 198
antidepressants (193) 193
induced weight-gain (193) 193
obesity (192) 192
internal medicine (191) 191
medicine, experimental (189) 189
risk (185) 185
antipsychotic agents - pharmacokinetics (179) 179
pharmacotherapy (178) 178
diagnosis (176) 176
severity of illness index (175) 175
psychology, clinical (174) 174
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4623) 4623
Spanish (11) 11
French (10) 10
German (10) 10
Italian (4) 4
Japanese (3) 3
Turkish (3) 3
Portuguese (2) 2
Polish (1) 1
Russian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | DEXAMETHASONE | PREVENTION | APREPITANT | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | DELAYED NAUSEA | CISPLATIN-INDUCED EMESIS | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 02/2014, Volume 86, Issue 2, pp. 133 - 144
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2013, Volume 167, Issue 3, pp. 301 - 314
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2016, Volume 24, Issue 2, pp. 675 - 682
Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In patients receiving highly emetogenic chemotherapy (HEC), its efficacy was... 
Pain Medicine | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Antiemetic therapy | Oncology | Highly-emetogenic chemotherapy | Cisplatin | Nursing Management/Nursing Research | Chemotherapy-induced nausea and vomiting | ORAL NEUROKININ-1 ANTAGONIST | EMETOGENIC CHEMOTHERAPY | DELAYED EMESIS | RELIEF | THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PLACEBO-CONTROLLED TRIAL | HIGH-DOSE CISPLATIN | QUALITY-OF-LIFE | Serotonin Antagonists - administration & dosage | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Genital Neoplasms, Female - drug therapy | Adult | Female | Nausea - drug therapy | Vomiting - prevention & control | Dexamethasone - administration & dosage | Morpholines - administration & dosage | Vomiting - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Isoquinolines - administration & dosage | Usage | Care and treatment | Chemotherapy | Dexamethasone | Clinical trials | Nausea | Cancer | Studies | Vomiting | Index Medicus
Journal Article
Schizophrenia Bulletin, ISSN 0586-7614, 2014, Volume 40, Issue 2, pp. 327 - 340
Some second-generation antipsychotics (SGAs) increase insulin resistance and fat oxidation, but counter intuitively they do not activate lipolysis. This seems... 
olanzapine | glucose | histamine | oxygen consumption | fat oxidation | risperidone | clozapine | body temperature | respiratory exchange ration | IN-VIVO OCCUPANCY | RECEPTOR ANTAGONISTS | PSYCHIATRY | GLUCOSE-TRANSPORT | ACID OXIDATION | ATYPICAL ANTIPSYCHOTICS | SKELETAL-MUSCLE | INSULIN-RESISTANCE | TERM WEIGHT-GAIN | ANIMAL-MODELS | PLASMA-GLUCOSE | Piperazines - administration & dosage | Clozapine - administration & dosage | Motor Activity - drug effects | Male | Quinolones - pharmacology | Aripiprazole | Terfenadine - administration & dosage | Dose-Response Relationship, Drug | Clozapine - pharmacology | Receptors, Histamine H1 - metabolism | Epoxy Compounds - pharmacology | Hypoglycemic Agents - administration & dosage | Time Factors | Astemizole - pharmacology | Epoxy Compounds - administration & dosage | Respiration - drug effects | Behavior, Animal - drug effects | Fatty Acids - metabolism | Terfenadine - pharmacology | Astemizole - administration & dosage | Benzodiazepines - pharmacology | Mice, Inbred C57BL - metabolism | Risperidone - administration & dosage | Risperidone - pharmacology | Piperazines - pharmacology | Hypoglycemic Agents - pharmacology | Antipsychotic Agents - administration & dosage | Quinolones - administration & dosage | Animals | Oxygen Consumption - drug effects | Drug Interactions - physiology | Benzodiazepines - administration & dosage | Mice | Antipsychotic Agents - pharmacology | Energy Metabolism - drug effects | Index Medicus | Regular
Journal Article
Drug Delivery, ISSN 1071-7544, 01/2017, Volume 24, Issue 1, pp. 181 - 187
Nimodipine (NM) is the only FDA-approved drug for treating subarachnoid hemorrhage induced vasospasm. NM has poor oral bioavailability (5-13%) due to its low... 
radiolabeling | Nimodipine | subarachnoid hemorrhage | lipo-pluronic micelles | Radiolabeling | Lipo-pluronic micelles | Subarachnoid hemorrhage | MANAGEMENT | EFFICACY | VESICLES | ANEURYSMAL SUBARACHNOID HEMORRHAGE | MIXED MICELLES | AGENT | NANOPARTICLES | TRANSPORT | PHARMACOLOGY & PHARMACY | OPTIMIZATION | OLANZAPINE | Injections, Intravenous | Vasodilator Agents - pharmacokinetics | Phosphatidylcholines - administration & dosage | Drug Carriers - administration & dosage | Half-Life | Biological Availability | Technetium | Tissue Distribution | Excipients - chemistry | Micelles | Vasodilator Agents - metabolism | Drug Compounding | Calcium Channel Blockers - metabolism | Poloxamer - administration & dosage | Poloxamer - chemistry | Drug Carriers - metabolism | Solubility | Phosphatidylcholines - chemistry | Excipients - administration & dosage | Administration, Intranasal | Blood-Brain Barrier - metabolism | Particle Size | Poloxalene - administration & dosage | Vasodilator Agents - blood | Nimodipine - metabolism | Animals | Calcium Channel Blockers - administration & dosage | Nimodipine - pharmacokinetics | Nimodipine - administration & dosage | Drug Carriers - pharmacokinetics | Mice | Poloxalene - chemistry | Calcium Channel Blockers - blood | Nimodipine - blood | Calcium Channel Blockers - pharmacokinetics | Vasodilator Agents - administration & dosage | Nanotechnology | Aneurysms | Bioavailability | Metabolism | Hemorrhage | Pharmacy | Pharmaceutical sciences | Index Medicus
Journal Article
Journal of Emergency Medicine, ISSN 0736-4679, 2014, Volume 46, Issue 6, pp. 808 - 813
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 08/2007, Volume 164, Issue 8, pp. 1214 - 1220
Journal Article
American Journal of Case Reports, ISSN 1941-5923, 05/2018, Volume 19, pp. 604 - 607
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 31, pp. 3558 - 3565
Journal Article